Adebrelimab plus chemo before surgery for advanced oral cancer
Treatments studied
Part of Cancer, Ear, nose & throat, Mouth & dental clinical trials.
This trial is testing a new combination of an immunotherapy drug (adebrelimab) plus two chemotherapy drugs (paclitaxel and carboplatin) given before surgery for advanced oral cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have oral squamous cell carcinoma that has been confirmed by a biopsy.
- You have not had any previous treatment for this cancer.
- Your cancer is stage IVB (meaning it has spread to nearby tissues or lymph nodes, but not to distant organs).
- You are generally active and able to do light work (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function are within certain limits (your doctor will check these).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies giving tislelizumab (an immune treatment) plus chemotherapy before surgery to shrink and treat locally advanced oral squamous cell cancer. It aims to improve tumor response and outcomes, while checking safety.
This trial tests a combination of three drugs (adebrelimab, carboplatin, and albumin-bound paclitaxel) before surgery for people with advanced mouth cancer that can be removed. The goal is to see if this treatment can help shrink the tumor and improve outcomes.
This trial tests if combining a low dose of radiation with an immunotherapy drug (adebrelimab) and a chemotherapy drug (albumin-bound paclitaxel) before surgery can help treat early-stage oral squamous cell carcinoma. It aims to see if this combination is safe and effective.
This trial tests whether adding an immunotherapy drug (sintilimab) to standard chemotherapy before and after surgery can improve outcomes for people with advanced oral squamous cell carcinoma. The treatment is given first to shrink the tumor, then again after surgery to help prevent recurrence.
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy before surgery for people with high-risk, hormone receptor-positive, HER2-negative breast cancer. The goal is to see if this approach can shrink tumors more effectively than chemotherapy alone.
This trial tests whether adding a PD-L1 antibody (Adabelimab) to standard chemotherapy before surgery can help treat advanced head and neck squamous cell carcinoma. It is for people who have not had treatment for this cancer before and are well enough to undergo the therapy.
Hear when a new Clinical IVb Stage Oral Squamous Cell Carcinomas Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.